Genetic and immunological markers predict titanium implant failure: a retrospective study
Genetic and immunological markers predict titanium implant failure: a retrospective study
复制标题
DOI：
10.1016/j.ijom.2012.07.018
复制
发表时间：
2013-04-01
影响因子：
2.4
通讯作者：
Schuett, S.
中科院分区：
文献类型：
--
作者：
Jacobi-Gresser, E.;Huesker, K.;Schuett, S.
这项研究评估了预测钛种植失败的诊断标记物。对109例接受钛种植手术的受试者进行种植效果评分，包括ILIA-889C/T(Rs1800587)、IL1B+3954C/T(Rs1143634)、IL1RN+2018 TIC(Rs419598)和TNFA-308G/A(Rs1800629)基因分型、治疗期间IL-1β/TNF-α释放试验和淋巴细胞转化试验。种植缺失的患者在钛刺激下的肿瘤坏死因子-α和IL-1β的释放显著增加(肿瘤坏死因子-α：256.89 pg/mlvs.81.4pg/ml；p<；0.0001；IL-1β：159.96 pg/mlvs.54.01pg/ml；p<；0.0001)。在种植体失败组中，IL1a：61%比42.6%，IL1B：53.7%比39.7%，TNFA：46.3%比30.9%，IL1RN：58.5%比52.9%。所研究的基因多态的风险基因数目的增加与种植体丢失的风险增加相关，这表明存在相加效应。多因素Logistic回归分析显示，IL-1β/肿瘤坏死因子α释放试验阳性积分(P<；0.0001，OR=12.01)和危险基因个数(P<；0.046，OR=1.5 7~6.0 1)与钛种植失败显著相关。IL-1/IL1RN/TNFA基因分型和细胞因子释放分析评分为钛种植体的预后提供了标记物，并可能为个体风险评估提供新的工具。
This study evaluates diagnostic markers to predict titanium implant failure. Retrospectively, implant outcome was scored in 109 subjects who had undergone titanium implant surgery, ILIA - 889 C/T (rs1800587), IL1B + 3954 C/T (rs1143634), IL1RN + 2018 TIC (rs419598) and TNFA - 308 G/A (rs1800629) genotyping, in vitro IL-1 beta/TNF-alpha release assays and lymphocyte transformation tests during treatment. TNF-alpha and IL-1 beta release on titanium stimulation were significantly higher among patients with implant loss (TNF-a: 256.89 pg/ml vs. 81.4 pg/ml; p < 0.0001; IL-1 beta: 159.96 pg/ml vs. 54.01 pg/ml; p < 0.0001). The minor alleles of the studied polymorphisms showed increased prevalence in the implant failure group (IL1A: 61% vs. 42.6% in controls, IL1B: 53.7% vs. 39.7% in controls, TNFA: 46.3% vs. 30.9% in controls, IL1RN: 58.5% vs. 52.9% in controls). Increasing numbers of risk genotypes of the studied polymorphisms were associated with an increasing risk of implant loss, suggesting an additive effect. Multiple logistic regression analysis showed positive IL-1 beta/TNF-alpha release assay scores (p < 0.0001, OR = 12.01) and number of risk genotypes (p < 0.046, OR = 1.57-6.01) being significantly and independently associated with titanium implant failure. IL-1/IL1RN/TNFA genotyping and cytokine release assay scores provide prognostic markers for titanium implant outcome and may present new tools for individual risk assessment.